Taiwan’s Formosa Pharmaceuticals (TPE: 6838) and US-based Eyenovia Inc., (NASDAQ: EYEN) have signed their second licensing and partnership agreement. Under this deal, Eyenovia has acquired exclusive US rights to commercialize APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%), a treatment for inflammation and pain following ocular surgery. The total value of the deal is reported to be USD 86 million, with specific terms undisclosed.
APP13007: A Nanotechnology-Based Ocular Treatment
Developed on Formosa’s APNT nanoparticle formulation platform, clobetasol propionate is a superpotent corticosteroid that offers a convenient twice-daily dosage regimen for 14 days of treatment. This drug has been filed for approval with the US FDA and has a PDUFA date set for March 4. If approved, APP13007 is anticipated to provide advantages over existing products and capture a significant share of the USD 1.3 billion market for topical ophthalmic steroids and steroid combinations in the US.
Building on a Successful Partnership
The two companies are no strangers to collaboration, having formed a partnership in February of this year to develop new therapies that combine Eyenovia’s Optejet dispensing technology with Formosa’s APNT nanoparticle formulation platform. This latest deal further solidifies their partnership and underscores their commitment to advancing ophthalmic treatments.-Fineline Info & Tech
